Poxel S.A.
$0.26+0.00%(+$0.00)
TickerSpark Score
69/100
60
Valuation
60
Profitability
100
Growth
24
Health
100
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PXXLF research report →
52-Week Range2% of range
Low $0.25
Current $0.26
High $0.70
Companywww.poxelpharma.com
Poxel S. A. , a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases.
- CEO
- Nicolas Trouche
- IPO
- 2017
- Employees
- 6
- HQ
- Lyon, FR
Price Chart
+4.00% · this period
Valuation
- Market Cap
- $13.95M
- P/E
- -0.96
- P/S
- 1.79
- P/B
- -0.21
- EV/EBITDA
- -23.65
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 51.56%
- Op Margin
- -30.30%
- Net Margin
- -178.45%
- ROE
- 22.71%
- ROIC
- 557.05%
Growth & Income
- Revenue
- $6.87M · 246.78%
- Net Income
- $-18,949,702 · 46.00%
- EPS
- $-0.44 · 51.65%
- Op Income
- $-4,493,890
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.70
- 52W Low
- $0.25
- 50D MA
- $0.26
- 200D MA
- $0.25
- Beta
- 1.31
- Avg Volume
- 8
Get TickerSpark's AI analysis on PXXLF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PXXLF Coverage
We haven't published any research on PXXLF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PXXLF Report →Similar Companies
EIGRQ+6.25%
Eiger BioPharmaceuticals, Inc.
$8.50
CRPOF-13.04%
Ceapro Inc.
$0.17
NOXOF+0.00%
Noxopharm Limited
$0.04
RDTCF+0.00%
Rapid Dose Therapeutics Corp.
$0.08
RXMD+5.50%
Progressive Care, Inc.
$2.11
TMDIF+2173.99%
Titan Medical Inc.
$0.82
BNOEF-14.89%
Bionomics Limited
$0.01
LVCLY+24.39%
Living Cell Technologies Limited
$0.03